16 unknown. 16 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Unknown 16 |
| Phase 2 | 4 | Unknown 4 |
Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers ZY19489 + Ferroquine (FQ), Placebo - Uncomplicated Malaria, Asymptomatic Condition | Phase 1 | Unknown | Zydus Lifesciences Limited | 36 | 2024-08-30 | 2024-10-01 |
| MSP3-CRM-Vac4All/ Alhydrogel® Vaccine MSP3-CRM-Vac4All/ Alhydrogel®, Anti-Rabies Vaccine - Malaria,Falciparum | Phase 1 / Phase 2 | Unknown | Vac4All | 465 | 2023-03-27 | 2023-04-26 |
| MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine MSP3-CRM-Vac4All/ Alhydrogel® - Malaria,Falciparum | Phase 1 | Unknown | Vac4All | 42 | 2021-12-01 | 2023-02-28 |
| A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults FMP013, ALFQ - Vaccine Reaction | Phase 1 | Unknown | U.S. Army Medical Research and Development Command | 46 | 2020-03-20 | 2023-01-10 |
| Monthly Versus Two Doses of Ante-Natal Intermittent Preventive Treatment With Sulphadoxine-Pyrimethamine Sulphadoxine-pyrimethamine - Malaria | Phase 1 | Unknown | University College Hospital, Ibadan | 136 | 2018-09-01 | 2018-07-26 |
| Plasmodium Immunotherapy for Lung Cancer Blood-stage infection of P. vivax - Lung Cancer, Nonsmall Cell | Phase 1 / Phase 2 | Unknown | State Key Laboratory of Respiratory Disease | 30 | 2016-06-27 | 2023-06-22 |
| Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA) Plasmodium falciparum sporozoite (PfSPZ) - Malaria | Phase 1 | Unknown | University of Oxford | 200 | 2016-05-01 | 2016-05-30 |
| Phase 1b Malaria Clinical Trial Using Argemone Mexicana in Healthy Adults in Mali Argemone mexicana - Malaria | Phase 1 | Unknown | University of Bamako | 24 | 2012-09-01 | 2012-10-03 |
| Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage) Lyophilised PEBS synthetic protein (PfPEBS), Rehydragel™ HPA - Malaria | Phase 1 / Phase 2 | Unknown | Vac4All | 36 | 2012-05-01 | 2012-05-25 |
| Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years GMZ 2 vaccine (GLURP + MSP 3), Rabies vaccine - Malaria | Phase 1 | Unknown | African Malaria Network Trust | 30 | 2008-06-01 | 2008-11-25 |
| Phase Ib Trial of MSP3 LSP in Children in Tanzania MSP 3 Long Synthetic Peptide, MSP3 vaccine, Hepatitis B vaccine - Malaria | Phase 1 | Unknown | African Malaria Network Trust | 45 | 2007-10-01 | 2007-12-14 |
| Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine GMZ2 (malaria vaccine), GMZ2 malaria vaccine, Verorab vaccine - Malaria | Phase 1 | Unknown | African Malaria Network Trust | 40 | 2007-06-01 | 2008-04-03 |
| Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) Malaria vaccine AMA1 (PfAMA-1-FVO[25-545], AMA1 - Malaria | Phase 1 | Unknown | African Malaria Network Trust | 40 | 2007-05-01 | 2008-04-03 |
| A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso MSP 3 Long Synthetic Peptide, Hepatitis B vaccine, Hepatitis B control vaccince - Malaria | Phase 1 | Unknown | African Malaria Network Trust | 45 | 2007-04-01 | 2008-05-07 |
| GMZ2-Aluminum Hydroxide Phase I, Tübingen GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine) - Malaria | Phase 1 | Unknown | European Vaccine Initiative | 30 | 2006-10-01 | 2007-08-10 |
| IPTi in Mozambican Infants for Malaria Prevention Sulfadoxine-Pyrimethamine (Fansidar) - Malaria | Phase 1 / Phase 2 | Unknown | Hospital Clinic of Barcelona | 1498 | 2002-09-01 | 2006-11-16 |
Malaria, Falciparum (5) · Asymptomatic Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Malaria, Vivax (1)
Infections (16) · Mosquito-Borne Diseases (16) · Parasitic Diseases (16) · Protozoan Infections (16) · Vector Borne Diseases (16) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Disease Attributes (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Aluminum Hydroxide (2) · Hepatitis B Vaccines (2) · Malaria Vaccines (2) · fanasil, pyrimethamine drug combination (2) · MSP3 protein, Plasmodium falciparum (181-276) (1) · Rabies Vaccines (1) · ZY-19489 (1) · ferroquine (1) · thrombospondin-related adhesive protein, protozoan (1)
African Malaria Network Trust (5) · Vac4All (3) · European Vaccine Initiative (1) · Hospital Clinic of Barcelona (1) · State Key Laboratory of Respiratory Disease (1) · U.S. Army Medical Research and Development Command (1) · University College Hospital, Ibadan (1) · University of Bamako (1) · University of Oxford (1) · Zydus Lifesciences Limited (1)
Mali (4) · Gabon (3) · Burkina Faso (1) · China (1) · Germany (1) · Kenya (1) · Mozambique (1) · Switzerland (1) · Tanzania (1) · United States (1)
Peter Kremsner, MD, PhD (3) · Clara Menendez, MD, PhD (1) · Dr. Deven Parmar, MD,FCP (1) · Francois Spertini, MD (1) · Issa Nebie, PhD (1) · Issaka Sagara, MD,MSPH (1) · John P Lusingu, MD, PhD (1) · Jurgen Knobloch, MD (1) · Mahamadou A Thera, MD MPH (1) · Mahamadou Thera, MD (1) · Manamadou Thera, MD (1) · Martha M Lemnge, MS, PhD (1) · Ming Ou-Yang, M.D. (1) · Philip Bejon, MD,PhD (1) · Pierre L Druilhe, MD (1)
PMID 18419347, PMID 19607731, PMID 19855847, PMID 21829466, PMID 21931708, PMID 27577237, PMID 31803847, PMID 34264864, PMID 35073864, PMID 35835738, PMID 36055874, PMID 37309249, PMID 37310872, PMID 42086568